CA2538494C - Composition permettant de moduler des parametres sanguins - Google Patents

Composition permettant de moduler des parametres sanguins Download PDF

Info

Publication number
CA2538494C
CA2538494C CA2538494A CA2538494A CA2538494C CA 2538494 C CA2538494 C CA 2538494C CA 2538494 A CA2538494 A CA 2538494A CA 2538494 A CA2538494 A CA 2538494A CA 2538494 C CA2538494 C CA 2538494C
Authority
CA
Canada
Prior art keywords
composition
supplement
cholesterol
phytosterols
essential fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2538494A
Other languages
English (en)
Other versions
CA2538494A1 (fr
Inventor
Alan Fergusson
John C. Davidson
John Charles Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2538494A priority Critical patent/CA2538494C/fr
Publication of CA2538494A1 publication Critical patent/CA2538494A1/fr
Application granted granted Critical
Publication of CA2538494C publication Critical patent/CA2538494C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/24—Cellulose or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pediatric Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Le brevet porte sur un supplément nutritionnel composé de phytostérols, d'anti-oxydants et d'autres complexes, y compris des acides gras essentiels, des acides aminés, des peptides, des polypeptides riches en proline et des enzymes digestives. Le supplément nutritionnel peut être utile aux personnes atteintes de maladies immunitaires, d'un cancer du sein, du colon ou de la prostate, d'une infection au VIH ou présentant une concentration élevée de cholestérol ou une hypertrophie de la prostate ou aux personnes vulnérables à ces maladies. Dans la forme à privilégier, le supplément comprend des phytostérols et des antioxydants, des acides gras essentiels dérivés d'acides aminés, des peptides à courte chaîne, des polypeptides riches en proline et des enzymes digestives et un diluant, soit la microcellulose.
CA2538494A 2006-02-24 2006-02-24 Composition permettant de moduler des parametres sanguins Active CA2538494C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2538494A CA2538494C (fr) 2006-02-24 2006-02-24 Composition permettant de moduler des parametres sanguins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2538494A CA2538494C (fr) 2006-02-24 2006-02-24 Composition permettant de moduler des parametres sanguins

Publications (2)

Publication Number Publication Date
CA2538494A1 CA2538494A1 (fr) 2007-08-24
CA2538494C true CA2538494C (fr) 2012-10-09

Family

ID=38433823

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2538494A Active CA2538494C (fr) 2006-02-24 2006-02-24 Composition permettant de moduler des parametres sanguins

Country Status (1)

Country Link
CA (1) CA2538494C (fr)

Also Published As

Publication number Publication date
CA2538494A1 (fr) 2007-08-24

Similar Documents

Publication Publication Date Title
US8772270B2 (en) Treatment methods requiring phyto-ingredients
US8507466B2 (en) Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
US20130303614A1 (en) Agent for inhibiting elevation in blood glucose level
AU2009200897A1 (en) Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides
JP2009525990A (ja) 医薬組成物
US20140314729A1 (en) Nutraceutical formulation for treatment of elevated cholesterol and cardiovascular disease
US20040234631A1 (en) Composition comprising soy and use thereof in the provention and/or treatment of various diseases
Bartnikowska Biological activities of phytosterols with particular attention to their effects on lipid metabolism
EP1644007B1 (fr) Composition comprenant un ou plusieurs phytosterols et/ou phytostanols et glucomannan, et utilisations de cette composition dans le traitement des troubles lipidiques chez des individus souffrant ou non du diabete du type ii
US8993551B2 (en) Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof
US20180243357A1 (en) Combined compositions for controlling blood sugar levels, hepatoprotection, and for prevention and treatment of related medical conditions
EP3481406B1 (fr) Composition
CA2538494C (fr) Composition permettant de moduler des parametres sanguins
US20120308586A1 (en) Composition based on extra virgin olive oils
US20050182037A1 (en) Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof
EP2405773A1 (fr) Stigmastérol pour le traitement de la maladie d'alzheimer
JP2010105948A (ja) 脂肪肝抑制剤
AU2017292732B2 (en) Composition
JP2006104080A (ja) 痛風と尿酸による血流障害の予防又は治療効果のある組成物及び健康食品。
Imran et al. Therapeutic implications of flaxseed peptides and bioactive components against various diseases
JP2019127470A (ja) リウマチ性疾患の治療用または予防用組成物
JP2005132835A (ja) 脂質代謝改善剤

Legal Events

Date Code Title Description
EEER Examination request